A randomized phase II study of AZ2014 versus everolimus in patients with VEGF refractory metastatic clear cell renal cancer (mRCC).

Thomas Powles(National Health Service), Christy Ralph(University of Leeds), Ekaterini Boleti(Royal Free London NHS Foundation Trust), Syed A. Hussain(University Hospitals Plymouth NHS Trust), Matthew Wheater(University Hospital Southampton NHS Foundation Trust), Andrew Stockdale(University Hospital Coventry), Shah‐Jalal Sarker(Queen Mary University of London), Omar Din(Sheffield Teaching Hospitals NHS Foundation Trust), Santhanam Sundar(Nottingham University Hospitals NHS Trust), Imtiaz Ahmed(Southend University Hospital NHS Foundation Trust), T. Geldart(Royal Bournemouth Hospital), Angus Robinson(Royal Sussex County Hospital)
Journal of Clinical Oncology
March 1, 2015
10.1200/jco.2015.33.7_suppl.409
Cited by 5

Related Papers

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|649